General Motors (GM) China Sales Rose 18% in August

General Motors (NYSE: GM) and its joint ventures delivered an August record 293,537 vehicles in China, which was up 18 percent year over year. The Cadillac, Buick, Chevrolet and Baojun brands reached all-time highs for the month.

“Our mainstream passenger car entries drove our sales momentum,” said GM Executive Vice President and GM China President Matt Tsien. “We are looking to build on our success by adding another five new and refreshed models in the final four months.”

Cadillac deliveries in August advanced 93 percent year over year to 9,914 units. Deliveries of the ATS-L luxury sedan and XT5 luxury crossover both exceeded 3,000 units. Sales of the XTS luxury sedan increased 65 percent from the same period a year earlier.

Buick deliveries in August rose 23 percent on an annual basis to 94,188 units, led by the Excelle GT sedan. The Envision SUV maintained its strong growth as well, with deliveries increasing 53 percent on an annual basis. Deliveries of the Verano family exceeded 13,000 units.

Chevrolet deliveries increased year over year to 38,706 units in August, led by demand of over 19,000 units for the Cruze family. The nameplate benefited from the arrival of the all-new Cruze in July. Chevrolet launched the Cavalier compact midsize family sedan last week and will introduce the sixth generation of its iconic Camaro muscle car later this month.

Baojun deliveries in August reached 51,099 units, an increase of 41 percent year over year. Sales of the Baojun 730 MPV and Baojun 560 SUV were up 37 percent and 52 percent respectively from the previous August.

Wuling deliveries continued to grow last month, despite the challenging market environment for the mini-commercial vehicle segment. Deliveries rose 8 percent year over year to 99,589 units, mainly driven by the strong performance of the Hong Guang MPV family.

In the first eight months of 2016, GM and its joint ventures’ deliveries in China increased 8.1 percent year over year to a record 2,374,542 units.

You May Also Be Interested In

• Pacific Bio (PACB) says prelim. revenue for Q1 was below expectations due to customers delaying instrument purchases
• Autonomix Medical (AMIX) Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
• AMD (AMD) Expands Commercial AI PC Portfolio